In America, 457 women have been diagnosed with the disease, known as breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. That’s up from 414 in the last report from federal regulators.
Totals for the potentially deadly disease, a form of non-Hodgkin’s Lymphoma, has risen steadily each year since 2011, when the FDA first issued warnings about certain implants.
Now, worldwide, more than 600 women have developed the disease with 16 dying from it. Nine have died in the U.S.
The FDA issued the news this week on the heels of requests from other nations for makers of textured implants, those primarily responsible for BIA-ALCL, to pull those products from the market.
The numbers are only expected to rise as more and more women learn about the cause of the disease.
In announcing the new figures, the FDA also disclosed that, for the first time, the agency is sending letters to doctors, specifically primary care physicians and gynecologists, urging them to become more aware of BIA-ALCL so that they can better diagnose their patients who may be at risk.
Other news from the agency about the disease and its response to it may be coming soon as the FDA plans to hold a meeting on March 25 and 26 to discuss breast implant-associated anaplastic large cell lymphoma.
Meanwhile, the number of lawsuits stemming from the disease also is rising as woman across the U.S. are turning to the courts for justice.
Ross Feller Casey, one of the nation’s top catastrophic injury law firms, is representing numerous women from across the nation who have acquired BIA-ALCL as a result of textured implants made by companies such as Mentor/Johnson & Johnson, Allergan/Actavis, and Sientra.
In fact, in April 2018, Ross Feller Casey filed what is believed to be the first suit in the U.S. against Johnson & Johnson and its subsidiaries relating to BIA-ALCL.
If you or a loved one has developed the disease, you should contact one of Ross Feller Casey’s BIA-ALCL lawyers now for a free consultation. The firm handles breast implant-associated anaplastic large cell lymphoma lawsuits on a contingency basis, so you will pay nothing until a financial recovery is made in your case.